Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase 1 Study to Assess Safety, Tolerability, Dosimetry, Pharmacokinetics and Imaging Properties of 89Zr-olaratumab (89ZrTLX300-CDx) in Participants With PDGFR Alpha Positive Solid Tumours and Soft Tissue Sarcoma

NCT06537596 is registered in ClinicalTrials.gov with Telix Pharmaceuticals (Innovations) Pty Ltd as lead sponsor.

NCT NCT06537596
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06537596 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase 1 Study to Assess Safety, Tolerability, Dosimetry, Pharmacokinetics and Imaging Properties of 89Zr-olaratumab (89ZrTLX300-CDx) in Participants With PDGFR Alpha Positive Solid Tumours and Soft Tissue Sarcoma
Lead sponsor
Telix Pharmaceuticals (Innovations) Pty Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
October 31, 2024
Completion date
December 31, 2027
Enrollment
50 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

pdgfr alpha positive solid tumours, soft tissue sarcoma